Echo Therapeutics Inc. completes a clinical trial of its Prelude SkinPrep transdermal drug delivery system, saying it will seek 510(k) clearance from the Food & Drug Administration in the "near future."

Echo Therapeutics Inc. (OTC:ECTE) announced the completion of a clinical trial of its Prelude SkinPrep transdermal drug delivery system, saying an application for 510(k) clearance from the Food & Drug Administration is imminent.
The Franklin, Mass.-based company launched the trial in April, in partnership with Ferndale Pharma Group Inc., to test the drug-device combination with Ferndale's 4 percent topical lidocaine. The needle-free system ablates a thin layer of skin before a drug is applied.
Covidien champions positive results for the Barrett's esophagus ablation device it acquired along...
Illinois healthcare giant Abbott lands European regulatory approval for the Xience Xpedition 48,...
ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist...
An attorney for a plaintiff suing robot-assisted surgical systems maker Intuitive Surgical says the...
The American Stroke Assn. and partners release the Spot a Stroke F.A.S.T. smartphone app to help...